Active substance
Metoclopramide
- SFDA 16
- US FDA 67
- Health Canada 10
- US price lines 4
- NHS prices 4
- WHO EML 2
- Safety 5
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| CLOPRAM 10 mg/2 ml solution for injection | 5 mg/ml | Solution for injection · Intramuscular and intravenous use | 5 Ampoule | SAR 9.00 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| PREMOSAN 10 mg injection | 10 mg | Injection · Parenteral use | 5 Ampoule | SAR 9.00 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| PREMOSAN 10 mg tablet | 10 mg | Tablet · Oral use | 20 Blister | SAR 6.70 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| PREMOSAN 10MG | 10 mg | Tablet · Oral use | 200 Blister | SAR 64.15 | Generic · Prescription | GULF PHARMACEUTICAL INDUSTIRES- JULPHAR | Valid |
| PREMOSAN ORAL DROPS 4MG-ML | 4 mg/ml | Oral drops · Oral use | 1 Bottle | SAR 2.85 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| PREMOSAN SYRUP 5MG-5ML | 1 mg/ml | Syrup · Oral use | 1 Bottle | SAR 3.85 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| PRIMPERAN TAB 10MG | 10 mg | Tablet · Oral use | 20 Blister | SAR 6.70 | NCE · Prescription | sanofi-aventis | Valid |
| METAGLIZ 10 MG TAB | 10 mg | Tablet · Oral use | 100 Blister | SAR 13.65 | Generic · Prescription | ALMIRALL PRODES PHARMA S.A. | Withdrawn by MAH · Not Marketed |
| METAGLIZ 10MG-5ML SOLUTION | 2 mg/ml | Syrup · Oral use | 1 Bottle | SAR 4.70 | Generic · Prescription | ALMIRALL PRODES PHARMA S.A. | Withdrawn by MAH · Not Marketed |
| METOSIL TAB 10MG | 10 mg | Film-coated tablet · Oral use | 20 Blister | SAR 5.45 | Generic · Prescription | SPIMACO ADDWAEIH | Invalid · Not Marketed |
| PRIMPERAN 5MG-ML 2ML-AMP. | 5 mg | Solution · Parenteral use | 6 Ampoule | SAR 11.35 | NCE · Prescription | sanofi-aventis | Invalid · Not Marketed |
| PRIMPERAN ADULT SUPP. 20MG | 20 mg | Suppository · Rectal use | 6 Blister | SAR 6.75 | Generic · Prescription | sanofi-aventis | Withdrawn by MAH · Not Marketed |
| PRIMPERAN CHILDREN SUPP. | 10 mg | Suppository · Rectal use | 6 Blister | SAR 4.55 | Generic · Prescription | sanofi-aventis | Withdrawn by MAH · Not Marketed |
| PRIMPERAN DROPS 0.1MG-DROP | 0.1 mg | Solution · Oral use | 1 Bottle | SAR 5.90 | NCE · Prescription | sanofi-aventis | Withdrawn by MAH · Not Marketed |
| PYLOMID 10MG TAB | 10 mg | Tablet · Oral use | 30 Blister | SAR 3.25 | Generic · Prescription | The Jordanian Pharmaceutical Manufacturing Medical Equipment Co. Ltd. (JPM) | Withdrawn by MAH · Not Marketed |
| RIAMIDE | 1 mg/ml | Syrup · Oral use | 1 Bottle | SAR 2.80 | Generic · Prescription | RIYADH PHARMA | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
ANESTHESIA-SUPPORTIVE AGENTS/ ASPIRATION PNEUMONIA PROPHYLAXIS; DYSPEPSIA; GASTROESOPHAGEAL REFLUX DISEASE (GERD); MENSTRUAL DISORDERS; MIGRAINE/ HEADACHE; NAUSEA AND VOMITING IN CANCER; PEPTIC ULCER; RENAL AND URETERIC STONES; VERTIGO - MOTION SICKNESS; VERTIGO -BENIGN PAROXYSMAL POSITIONAL VERTIGO AND ACUTE VESTIBULAR NEURONITIS OR LABYRINTHITIS
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| REGLAN | EQ 10MG BASE; EQ 5MG BASE | tablet · oral | ANI PHARMS | Prescription | 30 Dec 1980 |
| METOCLOPRAMIDE HYDROCHLORIDE | EQ 10MG BASE | tablet · oral | TEVA | Prescription | 29 Jul 1985 |
| METOCLOPRAMIDE HYDROCHLORIDE | EQ 10MG BASE; EQ 5MG BASE | tablet · oral | AIPING PHARM INC | Prescription | 30 Jan 1990 |
| METOCLOPRAMIDE HYDROCHLORIDE | EQ 5MG BASE/ML | injectable · injection | HOSPIRA | Prescription | 17 Jan 1991 |
| METOCLOPRAMIDE HYDROCHLORIDE | EQ 5MG BASE/5ML | solution · oral | PAI HOLDINGS | Prescription | 28 May 1991 |
| METOCLOPRAMIDE HYDROCHLORIDE | EQ 5MG BASE/ML | injectable · injection | TEVA PHARMS USA | Prescription | 27 Nov 1991 |
| METOCLOPRAMIDE HYDROCHLORIDE | EQ 5MG BASE | tablet · oral | TEVA | Prescription | 15 Jun 1993 |
| METOCLOPRAMIDE HYDROCHLORIDE | EQ 5MG BASE/5ML | solution · oral | ANI PHARMS | Prescription | 25 Jun 1993 |
| METOCLOPRAMIDE HYDROCHLORIDE | EQ 5MG BASE; EQ 10MG BASE | tablet · oral | STRIDES PHARMA INTL | Prescription | 28 Aug 2006 |
| METOCLOPRAMIDE HYDROCHLORIDE | EQ 5MG BASE; EQ 10MG BASE | tablet · oral | IPCA LABS LTD | Prescription | 12 Jun 2008 |
| METOCLOPRAMIDE HYDROCHLORIDE | EQ 5MG BASE/ML | injectable · injection | FRESENIUS KABI USA | Prescription | 19 Apr 2013 |
| METOCLOPRAMIDE | EQ 5MG BASE/ML | injectable · injection | AVET LIFESCIENCES | Prescription | 20 Dec 2013 |
| METOCLOPRAMIDE HYDROCHLORIDE | EQ 5MG BASE; EQ 10MG BASE | tablet, orally disintegrating · oral | NOVEL LABS INC | Prescription | 15 Aug 2014 |
| GIMOTI | EQ 15MG BASE/SPRAY | spray, metered · nasal | QOL MEDCL | Prescription | 19 Jun 2020 |
| METOCLOPRAMIDE HYDROCHLORIDE | EQ 5MG BASE/ML | injectable · injection | BAXTER HLTHCARE CORP | Prescription | 11 Sep 2026 |
| REGLAN | EQ 5MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; EQ 10MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | injectable · injection | HIKMA PHARMS | Discontinued | 7 Feb 1979 |
| REGLAN | EQ 5MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | solution · oral | ROBINS AH | Discontinued | 25 Mar 1983 |
| METOCLOPRAMIDE HYDROCHLORIDE | EQ 10MG BASE | tablet · oral | STRIDES PHARMA INTL | Discontinued | 17 Oct 1985 |
| CLOPRA-"YELLOW" | EQ 10MG BASE | tablet · oral | QUANTUM PHARMICS | Discontinued | 28 Oct 1985 |
| METOCLOPRAMIDE HYDROCHLORIDE | EQ 10MG BASE | tablet · oral | WATSON LABS | Discontinued | 22 Jan 1986 |
| METOCLOPRAMIDE HYDROCHLORIDE | EQ 10MG BASE/2ML | injectable · injection | LYPHOMED | Discontinued | 24 Jan 1986 |
| METOCLOPRAMIDE HYDROCHLORIDE | EQ 10MG BASE | tablet · oral | SCHERING | Discontinued | 2 Feb 1987 |
| METOCLOPRAMIDE HYDROCHLORIDE | EQ 10MG BASE | tablet · oral | MUTUAL PHARM | Discontinued | 10 Feb 1987 |
| METOCLOPRAMIDE HYDROCHLORIDE | EQ 10MG BASE/2ML | injectable · injection | SMITH AND NEPHEW | Discontinued | 2 Mar 1987 |
| METOCLOPRAMIDE HYDROCHLORIDE | EQ 10MG BASE | tablet · oral | SUPERPHARM | Discontinued | 26 Jun 1987 |
42 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| MAR-METOCLOPRAMIDE | 02517795 | 5 MG | TABLET · ORAL | MARCAN PHARMACEUTICALS INC |
| METOCLOPRAMIDE HYDROCHLORIDE INJECTION | 02185431 | 5 MG / ML | LIQUID · INTRAVENOUS; INTRAMUSCULAR | SANDOZ CANADA INCORPORATED |
| METOCLOPRAMIDE HYDROCHLORIDE INJECTION | 02531747 | 5 MG / ML | SOLUTION · INTRAVENOUS; INTRAMUSCULAR | BAXTER CORPORATION |
| METOCLOPRAMIDE HYDROCHLORIDE INJECTION | 02537397 | 5 MG / ML | SOLUTION · INTRAVENOUS; INTRAMUSCULAR | JAMP PHARMA CORPORATION |
| METOCLOPRAMIDE INJECTION USP | 02243563 | 5 MG / ML | SOLUTION · INTRAVENOUS; INTRAMUSCULAR | OMEGA LABORATORIES LIMITED |
| PMS-METOCLOPRAMIDE HYDROCHLORIDE INJECTION | 02510790 | 5 MG / ML | SOLUTION · INTRAMUSCULAR; INTRAVENOUS | PHARMASCIENCE INC |
| PMS-METOCLOPRAMIDE ORAL SOLUTION | 02230433 | 5 MG / 5 ML | SOLUTION · ORAL | PHARMASCIENCE INC |
| PMS-METOCLOPRAMIDE TABLETS | 02230431 | 5 MG | TABLET · ORAL | PHARMASCIENCE INC |
| PRZ-METOCLOPRAMIDE | 02548747 | 5 MG | TABLET · ORAL | PHARMARIS CANADA INC |
| PRZ-METOCLOPRAMIDE | 02548755 | 10 MG | TABLET · ORAL | PHARMARIS CANADA INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | METOCLOPRAMIDE 10 MG TABLET | $0.04394 | per EA | 23 Sep 2026 |
| US NADAC | METOCLOPRAMIDE 10 MG/2 ML VIAL | $0.52896 | per ML | 22 Jul 2026 |
| US NADAC | METOCLOPRAMIDE 5 MG TABLET | $0.0358 | per EA | 23 Sep 2026 |
| US NADAC | METOCLOPRAMIDE 5 MG/5 ML SOLN | $0.12569 | per ML | 23 Sep 2026 |
| NHS Drug Tariff | Metoclopramide 10mg tablets | £0.74 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Metoclopramide 10mg/2ml solution for injection ampoules | £5.19 | 10 ampoule | 1 Oct 2026 |
| NHS Drug Tariff | Metoclopramide 5mg tablets | £3.75 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Metoclopramide 5mg/5ml oral solution sugar free | £6.01 | 150 ml | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 2.3. Medicines for other common symptoms in palliative care · core
Palliative care
Oral > Liquid: 5 mg per 5 mL | Oral > Solid: 10 mg (hydrochloride) | Parenteral > General injections > unspecified: 5 mg per mL in 2 mL ampoule (hydrochloride) - 17.2. Antiemetic medicines · core
Nausea or vomiting
Oral > Liquid: 5 mg per 5 mL (EMLc) | Oral > Solid: 10 mg (scored) (hydrochloride) | Parenteral > General injections > unspecified: 5 mg per mL in 2 mL ampoule (hydrochloride)
Safety signals and safety-related labeling changes
- US FDA 9 Feb 2026 GIMOTI — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Drug Interactions; Patient Counseling Information / Patient Information / Medication Guide - US FDA 9 Feb 2026 REGLAN — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 9 Feb 2026 REGLAN — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 28 Feb 2019 METOZOLV ODT — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - MHRA 11 Dec 2014 Metoclopramide: risk of neurological adverse effects
Restricted dose and duration of use.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.